Chlorpromazine versus penfluridol for schizophrenia

Naemeh Nikvarz; Mostafa Vahedian; Navid Khalili

doi:10.1002/14651858.CD011831.pub2

Cochrane Database of Systematic Reviews

Clorpromazina versus penfluridol para la esquizofrenia

Información

DOI:

https://doi.org/10.1002/14651858.CD011831.pub2 Copiar DOI

Base de datos:

Cochrane Database of Systematic Reviews

Versión publicada:

23 septiembre 2017see what's new

Tipo:

Intervention

Etapa:

Review

Grupo Editorial Cochrane:

Grupo Cochrane de Esquizofrenia

Copyright:

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

Naemeh Nikvarz

Herbal and Traditional Medicines Research Center, Faculty of Pharmacy and Pharmaceutical Sciences, Kerman University of Medical Sciences, Kerman, Iran
Mostafa Vahedian

Department of Biostatistics and Epidemiology, Kerman University of Medical Sciences, Kerman, Iran
Navid Khalili

Correspondencia a: Department of Psychiatry, Kerman University of Medical Sciences, Kerman, Iran

[email protected]

Contributions of authors

Navid Khalili: Wrote the protocol, discussed allocation of responsibility for the tasks, selection of studies, data extraction, edited the Cochrane Schizophrenia Group template for the methods section, contributed in entering data in the Review Manager (RevMan) software, substantially contributed in writing and completing the primary draft of the manuscript and read and approved the final version of the review.

Mostafa Vahedian: Discussed allocation of responsibility for the tasks, selection of studies, data extraction, edited the Cochrane Schizophrenia Group template for the methods section, contributed in entering data in RevMan substantially contributed in writing and completing the primary draft of the manuscript and read and approved the final version of the review.

Naemeh Nikvarz: Discussed allocation of responsibility for the tasks, selection of studies, data extraction, contributed in entering data in RevMan and Grade profiler software, substantially contributed in writing and completing the primary draft of the manuscript and critically revised it and read and approved the final version of the review.

Sources of support

Internal sources

Kerman University of Medical Sciences, Kerman, Iran.

Employs lead author Naemeh Nikvarz and review author Navid Khalili. Review author Mostafa Vahedian is a student at this university.

External sources

No sources of support supplied

Declarations of interest

NK: No conflict of interest.

MV: No conflict of interest.

NN: No conflict of interest.

Acknowledgements

The Cochrane Schizophrenia Group Editorial Base in Nottingham produces and maintains standard text for use in the Methods section of their reviews. We have used this text as the basis of what appears here and adapted it as required.

The search term was developed by the Information Specialist of the Cochrane Schizophrenia Group and the contact author of this protocol. Jun Xia from Systematic Review Solutions extracted data of Chinese studies. We would like to thank Jamie Majdi and Pippa Shaw for peer reviewing this version of the review.

Parts of this review were generated using RevMan HAL v 4.0. You can find more information about RevMan here.

Version history

Published

Title

Stage

Authors

Version

2017 Sep 23

Chlorpromazine versus penfluridol for schizophrenia

Review

Naemeh Nikvarz, Mostafa Vahedian, Navid Khalili

https://doi.org/10.1002/14651858.CD011831.pub2

2015 Aug 15

Chlorpromazine versus penfluridol for schizophrenia

Protocol

Navid Khalili, Mostafa Vahedian, Naemeh Nikvarz, Mojtaba Piri

https://doi.org/10.1002/14651858.CD011831

Differences between protocol and review

We have reworded and regrouped the outcomes to more closely reflect the latest Cochrane Schizophrenia Group's methods template. Originally, the outcome of the adverse event/effect of death was the first outcome on our preferred 'Summary of fIndings' list. This seemed to strike an unfortunate, unwanted and inaccurate emphasis and for the full review we reordered outcomes.

Keywords

MeSH

Medical Subject Headings (MeSH) Keywords

Medical Subject Headings Check Words

Adult; Humans;

PICO

Population

Intervention

Comparison

Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Figure 1

Chlorpromazine structure

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 2

Penfluridol structure

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 3

Study flow diagram.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 4

'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 5

'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.1

Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 1 Service utilisation: 1. Hospital readmission.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.2

Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 2 Adverse effects: 1a. General ‐ needing antiparkinsonian medication.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.3

Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 3 Adverse effects: 1b. General ‐ need to reduce antipsychotic dose due to side effects.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.4

Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 4 Adverse effects: 2a. Specific ‐ extrapyramidal events (moderate or severe) ‐ short term.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.5

Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 5 Adverse effects: 2b. Specific ‐ extrapyramidal events (moderate or severe) ‐ medium term.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.6

Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 6 Adverse effects: 2c. Specific ‐ anticholinergic (moderate or severe) ‐ short term.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.7

Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 7 Adverse effects: 2d. Specific ‐ anticholinergic (moderate or severe) ‐ medium term.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.8

Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 8 Adverse effects: 2e. Specific ‐ central nervous system (moderate or severe) ‐ short term.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.9

Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 9 Adverse effects: 2f. Specific ‐ central nervous system (moderate or severe) ‐ medium term.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.10

Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 10 Adverse effects: 2g. Specific ‐ various other effects (moderate or severe) ‐ short term.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.11

Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 11 Adverse effects: 2h. Specific ‐ various other effects (moderate or severe) ‐ medium term.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.12

Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 12 Leaving the study early: 1a. Any reason.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.13

Comparison 1 CHLORPROMAZINE versus PENFLURIDOL, Outcome 13 Leaving the study early: 1b. Due to adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Table 2. Suggested design of study

Methods	Allocation: randomised, fully explicit description of methods of randomisation and allocation concealment. Blinding: single‐blind or double‐blind, but tested. Setting: anywhere. Duration: follow‐up to at least 52 weeks.
Participants	Diagnosis: schizophrenia. N = 300.* Age: adults. Sex: both.
Interventions	1. Chlorpromazine: oral‐maximum around 400 mg/day. N = 150. 2. Penfluridol: oral‐maximum around 80 mg/week. N = 150. Both groups could receive antiparkinsonian medication as required.
Outcomes	Service utilisation: Hospital admission, time to admission. Global state: Clinically significant response in global state, relapse. Mental state: Clinically significant response in mental state. Adverse effects: Clinically significant extrapyramidal side effects, death. Leaving the study early. Functioning: Employed, days working, in supportive relationship, healthy days. Economic outcomes.
Notes	* Powered to be able to identify a difference of ˜ 20% between groups for primary outcome with adequate degree of certainty.

Table 2. Suggested design of study

Ir a la tabla de la revisión

Chlorpromazine versus Penfluridol for schizophrenia
Patient or population: patients with schizophrenia Settings: hospital inpatients and outpatients Intervention: Chlorpromazine versus penfluridol
Outcomes	*Illustrative comparative risks (95% CI)**		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk³	Corresponding risk
	Penfluridol	Chlorpromazine
Service utilisation: hospital admission (short term)	150 per 1000	28 per 1000 (1 to 540)	RR 0.19 (0.01 to 3.60)	29 (1 study)	⊕⊕⊝⊝ low ^1,2
Global state: clinically important change in global state	See comment		Not estimable	0 (0)	See comment	No studies reported 'clinically important change in global state'. Change in global state was measure using global state scales but all data were presented without SD.
Global state: relapse	See comment		Not estimable	0 (0)	See comment	No studies reported this outcome.
Mental state: clinically important change in mental state	See comment		Not estimable	0 (0)	See comment	No studies reported 'clinically important change in mental state'. Change in mental state was measure using mental state scales but all data were presented without SD.
Adverse effect/event: clinically important extrapyramidal adverse events ‐ akathisia (medium term)	200 per 1000	38 per 1000 (8 to 212)	RR 0.19 (0.04 to 1.06)	85 (2 studies)	⊕⊕⊝⊝ low ^1,2	The same studies reported data for other extrapyramidal adverse events such as rigidity, tremor, dystonia and dyskinesia. There was no observable difference between chlorpromazine and penfluridol regarding any of these adverse effects.
Adverse effect/event: death	See comment		Not estimated	2 RCTs (0)	See comment	No deaths reported.
Leaving the study early: any reason (medium term)	400 per 1000	484 per 1000 (332 to 708)	RR 1.21 (0.83 to 1.77)	130 (3 studies)	⊕⊕⊝⊝ low ^1,2
The basis for the assumed risk* (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: risk ratio; SD: standard deviation
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.
¹ Serious risk of bias: downgraded by one level ‐ study had an unclear risk of bias for random sequence generation and blinding of assessors. ² Serious risk of imprecision: downgraded by one level ‐ studies had small sample sizes and number of events. ³ We have used the risk of an event in the penfluridol group within the trial/s the benchmark, rounding to nearest five for clarity of presentation in the table.

Ir a la tabla de la revisión

Table 1. Cochrane reviews on chlorpromazine for people with schizophrenia

Review title	Reference
Acetophenazine versus chlorpromazine	Bazrafshan 2015
Chlorpromazine dose for people with schizophrenia	Dudley 2009
Cessation of medication for people with schizophrenia already stable on chlorpromazine	Almerie 2007
Chlorpromazine versus atypical antipsychotic drugs for schizophrenia	Saha 2013
Chlorpromazine versus clotiapine for schizophrenia	Developing protocol
Chlorpromazine versus haloperidol for schizophrenia	Leucht 2008
Chlorpromazine versus metiapine	Zare 2015
Chlorpromazine versus penfluridol for schizophrenia	Current review
Chlorpromazine versus piperacetazine	Eslami 2015
Chlorpromazine versus placebo for schizophrenia	Adams 2014
Chlorpromazine for psychosis induced aggression or agitation	Ahmed 2010

Table 1. Cochrane reviews on chlorpromazine for people with schizophrenia

Ir a la tabla de la revisión

Comparison 1. CHLORPROMAZINE versus PENFLURIDOL

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Service utilisation: 1. Hospital readmission Show forest plot	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	0.19 [0.01, 3.60]

1.1 short term	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	0.19 [0.01, 3.60]
2 Adverse effects: 1a. General ‐ needing antiparkinsonian medication Show forest plot	2	74	Risk Ratio (M‐H, Fixed, 95% CI)	0.70 [0.51, 0.95]

2.1 short term	1	33	Risk Ratio (M‐H, Fixed, 95% CI)	0.82 [0.46, 1.46]
2.2 medium term	1	41	Risk Ratio (M‐H, Fixed, 95% CI)	0.63 [0.43, 0.91]
3 Adverse effects: 1b. General ‐ need to reduce antipsychotic dose due to side effects Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only

3.1 medium term	1	33	Risk Ratio (M‐H, Fixed, 95% CI)	0.74 [0.26, 2.06]
4 Adverse effects: 2a. Specific ‐ extrapyramidal events (moderate or severe) ‐ short term Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only

4.1 akatisia	1	33	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.2 dyskinesia	1	33	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.3 dystonia	1	33	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.4 rigidity	1	33	Risk Ratio (M‐H, Fixed, 95% CI)	0.15 [0.01, 2.90]
4.5 tremor	1	33	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
5 Adverse effects: 2b. Specific ‐ extrapyramidal events (moderate or severe) ‐ medium term Show forest plot	3		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only

5.1 akathisia	2	85	Risk Ratio (M‐H, Fixed, 95% CI)	0.19 [0.04, 1.06]
5.2 dyskinesia	2	85	Risk Ratio (M‐H, Fixed, 95% CI)	0.97 [0.14, 6.52]
5.3 dystonia	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	0.93 [0.06, 13.54]
5.4 muscle spasm	1	56	Risk Ratio (M‐H, Fixed, 95% CI)	3.0 [0.13, 70.64]
5.5 rigidity	2	70	Risk Ratio (M‐H, Fixed, 95% CI)	0.22 [0.04, 1.20]
5.6 tremor	2	85	Risk Ratio (M‐H, Fixed, 95% CI)	0.70 [0.14, 3.43]
6 Adverse effects: 2c. Specific ‐ anticholinergic (moderate or severe) ‐ short term Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only

6.1 constipation	1	33	Risk Ratio (M‐H, Fixed, 95% CI)	4.42 [0.60, 32.71]
6.2 dry mouth	1	33	Risk Ratio (M‐H, Fixed, 95% CI)	2.25 [0.10, 51.46]
6.3 increased salivation	1	33	Risk Ratio (M‐H, Fixed, 95% CI)	0.25 [0.01, 5.72]
7 Adverse effects: 2d. Specific ‐ anticholinergic (moderate or severe) ‐ medium term Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only

7.1 blurred vision	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	0.31 [0.01, 7.09]
7.2 constipation	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	3.73 [0.47, 29.49]
7.3 dry mouth	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	2.81 [0.12, 63.83]
8 Adverse effects: 2e. Specific ‐ central nervous system (moderate or severe) ‐ short term Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only

8.1 agitation	1	33	Risk Ratio (M‐H, Fixed, 95% CI)	2.25 [0.10, 51.46]
8.2 drowsiness	1	33	Risk Ratio (M‐H, Fixed, 95% CI)	8.25 [0.49, 137.94]
8.3 dizziness	1	33	Risk Ratio (M‐H, Fixed, 95% CI)	0.25 [0.03, 2.12]
8.4 insomnia	1	33	Risk Ratio (M‐H, Fixed, 95% CI)	2.25 [0.10, 51.46]
9 Adverse effects: 2f. Specific ‐ central nervous system (moderate or severe) ‐ medium term Show forest plot	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only

9.1 drowsiness	2	85	Risk Ratio (M‐H, Fixed, 95% CI)	1.05 [0.54, 2.05]
9.2 dizziness	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	0.47 [0.05, 4.60]
9.3 excitement	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	2.81 [0.12, 63.83]
9.4 faintness	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	0.93 [0.15, 5.76]
9.5 insomnia	2	85	Risk Ratio (M‐H, Fixed, 95% CI)	0.17 [0.03, 0.93]
10 Adverse effects: 2g. Specific ‐ various other effects (moderate or severe) ‐ short term Show forest plot	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only

10.1 heartburn	1	33	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
10.2 increased alkaline phosphatase, bilirubin, SGOT	1	56	Risk Ratio (M‐H, Fixed, 95% CI)	0.33 [0.01, 7.85]
10.3 systemic allergic reaction	1	33	Risk Ratio (M‐H, Fixed, 95% CI)	5.25 [0.29, 94.14]
11 Adverse effects: 2h. Specific ‐ various other effects (moderate or severe) ‐ medium term Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only

11.1 depression	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	0.19 [0.01, 3.60]
11.2 decreased sexual drive	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	0.47 [0.05, 4.60]
11.3 impotence	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	2.81 [0.12, 63.83]
11.4 photosensitivity	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	2.81 [0.12, 63.83]
11.5 poor appetite	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	0.93 [0.06, 13.54]
12 Leaving the study early: 1a. Any reason Show forest plot	3		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only

12.1 medium term	3	130	Risk Ratio (M‐H, Fixed, 95% CI)	1.21 [0.83, 1.77]
13 Leaving the study early: 1b. Due to adverse events Show forest plot	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only

13.1 short term	1	33	Risk Ratio (M‐H, Fixed, 95% CI)	6.75 [0.39, 116.00]
13.2 medium term	2	74	Risk Ratio (M‐H, Fixed, 95% CI)	1.53 [0.72, 3.28]

Comparison 1. CHLORPROMAZINE versus PENFLURIDOL

Ir a la tabla de la revisión

The Cochrane Library

Scolaris Language Selector Scolaris Language Selector

Idioma de la Revisión Cochrane

Idioma de la web

Scolaris Content Language Banner Portlet Scolaris Content Language Banner Portlet

Scolaris Content Display Scolaris Content Display

Clorpromazina versus penfluridol para la esquizofrenia

Información